NCT06947304 - Evaluation of Miricorilant on Liver Fat in Patients With MASLD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 22, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Nonalcoholic Steatohepatitis (NASH)Metabolic Dysfunction-Associated Steatohepatitis (MASH)Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Non-alcoholic Fatty Liver Disease (NAFLD)

Interventions

DRUG

Miricorilant

100 mg administered orally, once daily

Trial Locations (1)

65211

RECRUITING

University of Missouri, Columbia